Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior    INDV   GB00BRS65X63

INDIVIOR

(INDV)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Indivior : Court Denies Emergency Motion to Block Dr. Reddy's Generic Medicine Launch

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 03:00am EDT

By Carlo Martuscelli

Indivior said Tuesday that a U.S. court has denied it an emergency motion that would have blocked Dr. Reddy's Laboratories Ltd.'s (500124.BY) plans to launch a generic version of the U.K.-listed company's opioid-addiction treatment.

The court ordered that a mandate be issued on Feb. 19 voiding a previous preliminary injunction stopping the Indian pharmaceutical from bringing its generic medicine to market. Indivior said it will file a petition to stay the mandate with the U.S. Supreme Court.

The U.K.-listed pharmaceutical company is in a legal battle to stop rivals from bringing to market generic alternatives of its Suboxone drug-addiction medication. The company alleges that the Indian company Dr. Reddy's, as well as competitor Alvogen, are infringing on its patents.

Indivior had previously been granted a stop-order against Dr. Reddy's barring it from selling its Suboxone generic, but this was overturned in November, sending shares of the company plummeting. Since then it has engaged with the courts to have the decision revoked.

Indivior said that it expects Dr. Reddy's to resume the launch of its U.S. product once the mandate that formally vacates the preliminary injunction is issued on Feb. 19. Given a previous agreement it struck with Alvogen, the U.S. rival will also begin selling its version of Suboxone at the same time.

Indivior had previously said that, based on precedent, this could result in Suboxone losing 80% of its market share in a matter of months.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LTD -1.12% 2892.25 End-of-day quote.11.79%
INDIVIOR -1.88% 39.7175 Delayed Quote.-63.96%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INDIVIOR
04/16INDIVIOR : US charges drugmaker Indivior, Reckitt over opioid healthcare fraud
AQ
04/15LONDON STOCK EXCHANGE : London's FTSE 100 subdued, IWG lifts midcaps
RE
04/11LONDON STOCK EXCHANGE : Brexit delay lifts mid-caps to six-month high; growth fe..
RE
04/11INDIVIOR : RB Group Plc - US Justice Department indictment of Indivior Plc
AQ
04/11INDIVIOR : Virginia drug company charged in billion-dollar opioid marketing frau..
AQ
04/11Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptio..
RE
04/11Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptio..
RE
04/11U.K. Drugmaker Charged -- WSJ
DJ
04/11INDIVIOR : shares collapse after US fraud indictment
AQ
04/11INDIVIOR : FTSE 100 inches lower as Indivior share price tanks
AQ
More news
Financials ($)
Sales 2019 472 M
EBIT 2019 -6,06 M
Net income 2019 -12,0 M
Finance 2019 115 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 7,25
EV / Sales 2019 0,57x
EV / Sales 2020 0,54x
Capitalization 381 M
Chart INDIVIOR
Duration : Period :
Indivior Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIVIOR
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 1,61 $
Spread / Average Target 208%
EPS Revisions
Managers
NameTitle
Shaun Thaxter Chief Executive Officer & Executive Director
Howard H. Pien Chairman
Mark Crossley Chief Financial Officer & Executive Director
Christian Heidbreder Chief Scientific Officer
Ingo Elfering Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
INDIVIOR-63.96%381
WUXI APPTEC CO LTD17.69%15 168
MERCK KGAA5.71%13 690
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD32.74%10 308
KYOWA HAKKO KIRIN CO LTD4.49%10 229
JAZZ PHARMACEUTICALS PLC4.36%7 333